Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting
- Interim data from the AMDS PERSEVERE clinical trial demonstrates a meaningful reduction of all-cause mortality, with 79% of participants experiencing no major adverse events at 30-days post-implantation.
- The interim data also shows excellent results for additional endpoints, including technical success and absence of certain complications.
- The absence of distal anastomotic new entry (DANE) tears, which are associated with increased mortality, is particularly notable.
- The use of AMDS offers substantial clinical benefit and minimal time and complexity to the procedure.
- None.
Interim Data Demonstrate Meaningful Reduction of All-Cause Mortality with AMDS
Dr. Fernando Fleischman, Associate Professor of Clinical Surgery at Keck Hospital of the University of
Interim data demonstrate clinically meaningful reduction of all-cause mortality and primary major adverse events (MAEs), with
PERSERVERE (%) | Historical Reference1 (%) | |
All-cause mortality | 13.5 | 29-44 |
New disabling stroke | 9.6 | 12-35 |
New onset renal failure requiring dialysis | 7.7 | 12-43 |
Myocardial infarction | 0.0 | 7-15 |
Interim data also demonstrate excellent results for additional endpoints:
PERSEVERE (%) | |
Technical Success | 98.3 |
Unanticipated aortic reoperations | 1.7 |
Distal anastomotic new entry (DANE) tears | 0.0 |
Distal stent-induced new entry (d-SINE) | 0.0 |
Occlusion of Supra-aortic vessels | 0.0 |
New Post-op Paraplegia or Paraparesis | 0.0 |
The interim data compares favorably with expected rates of early reintervention and DANE tears in this patient population. DANE occurs in 25
Dr. Fleischman said, "The current standard of care to manage acute Type I aortic dissections is technically meticulous and often leads to distal anastomotic new entry tears, or DANE tears, which are associated with increased risk for re-intervention and mortality. I am encouraged by the interim results of the PERSEVERE study which indicate that the use of AMDS offers substantial clinical benefit, notably the absence of DANE tears and an improved all-cause mortality rate, for patients presenting with malperfusion and ADTI dissection at 30-days, while adding minimal time and complexity to the procedure."
"We are incredibly pleased with the overwhelmingly positive interim results of the PERSEVERE trial which have demonstrated the lifesaving nature of AMDS, including reduction of stroke, new onset renal failure requiring dialysis and myocardial infraction," said Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion. "Given there is no alternative solution on the market today, we are excited to complete this trial and submit our PMA to FDA as expeditiously as possible."
About the AMDS PERSERVE Clinical Trial
The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial to determine if patients with acute DeBakey Type I aortic dissection can be treated safely and effectively using the AMDS Hybrid Prosthesis. The trial is designed to support the company's forthcoming application to the
About the AMDS Hybrid Prosthesis and DeBakey Type I Aortic Dissections
The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute Type I aortic dissections. It is used as a complement to, and in conjunction with, hemiarch replacement without adding technical complexity. The design of the AMDS allows for rapid deployment of the graft in the aortic arch during a standard replacement of the ascending aorta, with deployment adding minimal time to the procedure time. The deployment of the AMDS preserves the native arch, potentially allowing for minimally invasive re-interventions, including the repair of additional entry tears, rather than an invasive arch repair. AMDS is available in select markets around the world including
Globally, approximately 48,000 patients suffer from acute Stanford Type A aortic dissections annually, an estimated
About Artivion, Inc.
Headquartered in suburban
References
- Zindovic I et al. J Thorac Cardiovasc Surg 2019; Pacini D et al. Eur J Cardiothorac Surg 2013; Girdauskas E. et al. J Thorac Cardiovasc Surg 2009; Geirsson A. et al J Thorac Cardiovasc Surg 2007; Bossone E. et al Am J Cardiol 2002
- Ravesh M. et al. J Thorac Dis 2021
- Bing F et al. Vasc Endovasc Surg 2014, Ergin M, et al Ann Thorac Surg 1994, Rylski B et al. Eur J Cardiothorac Surg, 2017, Tamura K et al, Eur J Cardiothorac Surg 2017
- Reference: Bozso et al: The Journal of Thoracic and Cardiovascular Surgery (2022), doi: https://doi.org/10.1016/j.jtcvs.2022.08.040
Contacts:
Artivion | Gilmartin Group LLC |
D. Ashley Lee | Brian Johnston / Lynn Lewis |
Executive Vice President & | Phone: 332-895-3222 |
Chief Financial Officer | |
Phone: 770-419-3355 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-presentation-of-late-breaking-interim-data-from-amds-persevere-trial-at-the-37th-european-association-for-cardio-thoracic-surgery-annual-meeting-301948892.html
SOURCE Artivion, Inc.
FAQ
What are the interim results of the AMDS PERSEVERE clinical trial?
What are the additional positive outcomes from the interim data?
Why are the absence of DANE tears significant?
What are the benefits of using AMDS?